首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 基因療法

市場調查報告書

商品編碼

1562466

基因治療市場規模、佔有率、成長分析、按類型、按載體、按治療領域、按給藥途徑、按給藥方式、按地區 - 行業預測，2024-2031 年

Gene Therapy Market Size, Share, Growth Analysis, By Type, By vector, By therapeutic area, By route of administration, By delivery method By Region - Industry Forecast 2024-2031

出版日期: 2024年09月10日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球基因治療市場規模將為74.1億美元，從2023年的90億美元成長到2031年的424.6億美元，預計預測期內（2024-2031年）複合年成長率為21.4%。

由於分子生物學和基因研究的進步，全球基因治療市場正在經歷顯著成長。基因治療涉及修改或操縱基因來治療或預防疾病，針對疾病的根本原因，而不是簡單地治療症狀。這個市場正在蓬勃發展，因為它可以治療多種疾病，包括遺傳性疾病、癌症和病毒感染疾病。此外，傳統治療方法無效的罕見疾病的日益普及也推動了對基因治療解決方案的需求。近年來，許多基因治療產品獲得了監管部門的核准，標誌著治療格局的轉變。市場按載體類型（病毒、非病毒）、應用（癌症、罕見疾病、心血管、神經系統等）及遞送方法（體內、離體）進行細分。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Novartis AG（Switzerland）
Biogen Inc.（US）
Gilead Sciences, Inc.（US）
Bristol-Myers Squibb（US）
Alnylam Pharmaceuticals, Inc.（US）
Sarepta Therapeutics, Inc.（US）
Amgen, Inc.（US）
Orchard Therapeutics PLC（UK）
F. Hoffmann-La Roche AG（Switzerland）
Jazz Pharmaceuticals PLC（Ireland）
uniQure NV（Netherlands）
Johnson & Johnson（US）
bluebird bio, Inc.（US）
BioMarin Pharmaceutical Inc.（US）
Krystal Biotech, Inc.（US）
Shanghai Sunway Biotech Co. Ltd.（China）
Sibiono Genetech Co. Ltd.（China）
Ferring BV（Netherlands）
Vertex Pharmaceuticals Incorporated（US）
Pfizer, Inc.（US）

簡介目錄

Product Code: SQMIG35H2218

Global Gene Therapy Market size was valued at USD 7.41 billion in 2022 and is poised to grow from USD 9.0 billion in 2023 to USD 42.46 billion by 2031, at a CAGR of 21.4 % during the forecast period (2024-2031).

Global gene therapy market has witnessed significant growth, driven by advances in molecular biology and genetic research. Gene therapy involves modifying or manipulating genes to treat or prevent diseases, targeting the underlying cause of the condition rather than merely treating symptoms. The market has gained momentum due to its potential to treat a wide range of diseases, including genetic disorders, cancers, and viral infections. Furthermore, the increasing prevalence of rare diseases, for which traditional therapies have been ineffective, is propelling the demand for gene therapy solutions. In recent years, numerous gene therapy products have received regulatory approvals, signaling a shift in the therapeutic landscape. The market is segmented based on vector types (viral and non-viral), applications (cancer, rare diseases, cardiovascular, neurological, and others), and delivery methods (in vivo and ex vivo).

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gene Therapy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gene Therapy Market Segmental Analysis

Global Gene Therapy Market is segmented on the basis of type, vector, therapeutic area, route of administration, delivery mode, and region. By type, market is segmented into gene silencing, cell replacement, gene augmentation, other therapies. By vector, market is segmented into viral vectors, and non-viral vectors. By therapeutic area, market is segmented into Neurology, Oncology, Hepatology, and Other Therapeutic areas. By route of administration, market is segmented into intravenous, and other routes of administration. By delivery method, market is segmented into IN VIVO, and EX VIVO. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Gene Therapy Market

One key driver of the gene therapy market is the increasing prevalence of genetic disorders. Conditions such as cystic fibrosis, hemophilia, and muscular dystrophy, which are caused by inherited genetic mutations, have traditionally been challenging to treat effectively. Gene therapy offers a novel solution by targeting the underlying genetic defects, potentially providing long-term or permanent treatment options. As diagnostic tools like next-generation sequencing (NGS) become more accessible and widely used, the identification of genetic conditions is increasing, further driving demand for innovative treatments. The rise in newborn screening and genetic counseling has also contributed to early detection, allowing gene therapies to play a crucial role in early intervention. Additionally, with growing awareness and acceptance of precision medicine, healthcare providers are increasingly adopting gene therapy as a solution for patients with genetic disorders.

Restraints in the Global Gene Therapy Market

A major restraint for the gene therapy market is the prohibitive cost of treatment. Gene therapies like Zolgensma and Luxturna, which are approved for conditions like spinal muscular atrophy and retinal dystrophy, come with price tags reaching several million dollars per patient. These high costs limit the accessibility of such treatments, especially in regions with limited healthcare funding or underdeveloped insurance systems. The production of gene therapies involves complex and costly processes, from R&D to manufacturing and clinical trials. The reliance on viral vectors for delivery, which require specialized manufacturing facilities, adds to the financial burden. Moreover, the regulatory approval pathway for gene therapies is often lengthy and rigorous, further increasing development costs. Until costs can be reduced through advancements in technology or improved insurance coverage, the broad adoption of gene therapies will face challenges.

Market Trends of the Global Gene Therapy Market

A significant trend shaping the gene therapy market is the rise in strategic collaborations and partnerships among pharmaceutical companies, biotech firms, and research institutions. Given the complexities involved in developing gene therapies-ranging from R&D to regulatory approval-companies are joining forces to pool resources, share knowledge, and accelerate product development. Collaborations have proven successful in expediting clinical trials and gaining regulatory approvals. For example, partnerships between Novartis and Avexis or Pfizer and Spark Therapeutics have helped bring gene therapies to market more efficiently. These alliances also foster innovation in gene delivery methods, particularly viral vectors, which are crucial to the effectiveness of gene therapies. As more companies recognize the potential of shared expertise, the gene therapy market is likely to witness further collaborative efforts aimed at speeding up innovation and improving treatment accessibility.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Ecosystem of the Market
Top Investment Analysis
Key Success Factor
Degree of Competition
Technology Analysis
Value Chain Analysis
Pipeline Products Analysis
Patent Analysis
Supply Chain Analysis
Regulatory Analysis
Pricing Analysis

Gene Therapy Market by Type

Market Overview
Gene Silencing
Cell Replacement
Gene Augmentation
Other Therapies

Gene Therapy Market by Vector

Market Overview
Viral Vectors
- Retroviral Vectors
- Gamma Retroviral Vectors
- Lentiviral Vectors
- Adeno-Associated Viral Vectors
- Other Viral Vectors
Non-Viral Vectors
- Oligonucleotides
- Other Non-Viral Vectors

Gene Therapy Market by Therapeutic Area

Market Overview
Neurology
Oncology
Hepatology
Other Therapeutic Areas

Gene Therapy Market by Route of Administration

Market Overview
Intravenous
Other Routes of Administration

Gene Therapy Market by Delivery Method

Market Overview
IN VIVO
EX VIVO

Gene Therapy Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alnylam Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sarepta Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orchard Therapeutics PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jazz Pharmaceuticals PLC (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
uniQure N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bluebird bio, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioMarin Pharmaceutical Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Krystal Biotech, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai Sunway Biotech Co. Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sibiono Genetech Co. Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ferring B.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vertex Pharmaceuticals Incorporated (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments